Results 11 to 20 of about 23,011 (205)
Evaluation of CD30 expression in B ALL and its correlation with MRD(Minimum Residual Disease)
Journal of Research in Medical Sciences, 2021 Background: This study was conducted to evaluate CD30 expression in minimum residual disease after chemotherapy in B-acute lymphoblastic leukemia (B-ALL).
Amirhossein Kazemian, Pardis Nematollahi
doaj +1 more source
Zhongliu Fangzhi Yanjiu, 2021 Objective To explore the application value of treatment-related markers PD-L1, PD-L2, CD30, CD23, BCL-2, BCL-6, MUM1 and GATA3 in the diagnosis and prognostic evaluation of primary mediastinal B-cell lymphoma(PMBL).
YUAN Ting +4 more
doaj +1 more source
Asian Pacific Journal of Cancer Biology, 2020 Background: Diffuse large B-cell lymphoma (DLBCL) is the most common subtype (68.2%) of B cells Non Hodgkin Lymphoma in Indonesia. This tumor heterogeneity is characterized by a variety of clinical conditions, morphology, genetic profiles, therapeutic ...
Maria Reynelda Santoso +3 more
doaj +1 more source
The standardization of immunohistochemical detection and interpretation of CD30 expression in lymphomas [PDF]
Zhongguo aizheng zazhi, 2023 CD30 can be expressed in a variety of lymphoma subtypes, among which classical Hodgkin lymphoma (CHL) and anaplastic large cell lymphoma (ALCL) are the most common ones.
CD-Positive Lymphoma Pathology Expert Group
doaj +3 more sources
Artificial Cells, Nanomedicine, and Biotechnology, 2020 Overexpression of CD30 has been reported on the surface of some T-cell lymphomas, especially on Hodgkin’s lymphoma (HL) and anaplastic large cell lymphoma (ALCL). CD30 targeted immunotherapy has good clinical therapy response.
Jianhua Gong +5 more
doaj +1 more source
Clinical & Translational Immunology, 2021 Objectives Adoptive cell therapy (ACT) with mature T cells modified with a chimeric antigen receptor has demonstrated improved outcome for B‐cell malignancies.
Carmen Alvarez‐Fernández +8 more
doaj +1 more source
CD30+ lymphoproliferative disorders [PDF]
Haematologica, 2010 CD30 antigen, originally identified as a cell surface marker of the malignant Hodgkin and Reed-Sternberg (HRS) cells in Hodgkin’s lymphoma by the use of the Ki-1 monoclonal antibody, is a transmembrane glycoprotein member of the tumor necrosis factor (TNF) receptor superfamily.[1][1] In ...
de Leval, L., Gaulard, P.
openaire +3 more sources
CD30+ Lymphoproliferative Disorders as Potential Candidates for CD30-Targeted Therapies
Archives of Pathology & Laboratory Medicine, 2022 Context.— In the early 1980s, a monoclonal antibody termed Ki-1 was developed against a cell line derived from a patient with Hodgkin lymphoma. This antibody detected a limited number of benign activated lymphocytes in lymphoid tissue, whereas in Hodgkin lymphoma it appeared to be nearly specific for Reed ...
Roland, Schwarting +4 more
openaire +2 more sources
Mechanism of action and therapeutic targeting of CD30 molecule in lymphomas
Frontiers in Oncology, 2023 At present, the treatment of lymphoma has entered the era of precision medicine, and CD30, as a transmembrane protein, has become an important marker to help the diagnosis and formulation of treatment plans for lymphomas. This protein is widely expressed
Zhaoxia Li, Wei Guo, Ou Bai
doaj +1 more source
The expression of CD30 based on immunohistochemistry predicts inferior outcome in patients with diffuse large B-cell lymphoma. [PDF]
PLoS ONE, 2015 The prognostic value of CD30 expression in diffuse large B-cell lymphoma (DLBCL)remains controversial. Herein, we performed this retrospective study to investigate the clinical and prognostic significance of CD30 expression in patients with DLBCL.Among ...
Xiaoxiao Hao +7 more
doaj +1 more source